← Leaderboards
Michael R McDevitt
Sloan-Kettering Inst Can Research
$1,859,572
Attributed
$1,859,572
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $341.6K · FY2007–15$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$1,859,572 · 2
By mechanism
R01$1,297,572 · 1
R21$562,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jan Grimm$17,140,928
- Paul Bernard Romesser$1,968,392
- Luis F Parada$23,930,635
- Kyung Peck$213,639
- Charles Ross Schmidtlein$473,658
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsRadioisotopesDrug KineticsPharmaceutical PreparationsTumorTumor GrowthCytotoxicDesignEventModalityRetinal DiseasesTreatment EfficacyBinding (Molecular Function)BiodistributionAlpha ParticlesCellsBlood VesselsArthritisEndotheliumEpitopesGrowthNeovasculatureAntibodiesAnaplastic Astrocytoma
Grant awards (7)
Improving therapy of glioblastoma multiforme by enhancing therapeutic drug delive$341,566
R01 · FY2015 · CA · contact PI
Improving therapy of glioblastoma multiforme by enhancing therapeutic drug delive$331,320
R01 · FY2014 · CA · contact PI
Improving therapy of glioblastoma multiforme by enhancing therapeutic drug delive$321,072
R01 · FY2013 · CA · contact PI
Improving therapy of glioblastoma multiforme by enhancing therapeutic drug delive$303,614
R01 · FY2012 · CA · contact PI
Novel Nano-Constructs to Target and Destroy Tumor Neovasculature$187,000
R21 · FY2009 · CA · contact PI
Novel Nano-Constructs to Target and Destroy Tumor Neovasculature$187,000
R21 · FY2008 · CA · contact PI
Novel Nano-Constructs to Target and Destroy Tumor Neovasculature$188,000
R21 · FY2007 · CA · contact PI